BNP Paribas Financial Markets Buys New Holdings in Alumis Inc. (NASDAQ:ALMS)

BNP Paribas Financial Markets bought a new position in Alumis Inc. (NASDAQ:ALMS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,567 shares of the company’s stock, valued at approximately $27,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Maven Securities LTD bought a new position in shares of Alumis in the 2nd quarter worth approximately $332,000. Towerview LLC increased its position in shares of Alumis by 22.6% during the third quarter. Towerview LLC now owns 380,000 shares of the company’s stock valued at $4,058,000 after acquiring an additional 70,000 shares in the last quarter. Charles Schwab Investment Management Inc. bought a new position in shares of Alumis during the third quarter valued at $1,160,000. Millennium Management LLC bought a new stake in shares of Alumis in the second quarter worth approximately $3,376,000. Finally, Ally Bridge Group NY LLC bought a new position in shares of Alumis during the 2nd quarter valued at $8,229,000.

Analyst Ratings Changes

Several research analysts have weighed in on ALMS shares. Robert W. Baird initiated coverage on shares of Alumis in a research report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $26.00 target price on shares of Alumis in a research report on Friday. Baird R W raised Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Alumis presently has a consensus rating of “Buy” and a consensus target price of $26.83.

Alumis Trading Up 2.2 %

Shares of NASDAQ ALMS opened at $8.82 on Friday. The business has a 50 day simple moving average of $10.21. Alumis Inc. has a fifty-two week low of $7.66 and a fifty-two week high of $13.53.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.